Pause in the Use of Johnson & Johnson COVID-19 VACCINE
FDA STATEMENT
For Immediate Release:
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.
CT DEPT of PUBLIC HEALTH STATEMENT
For Immediate Release:
Early this morning, the U.S. FDA and CDC issued a joint statement recommending a pause on the use of the Johnson & Johnson (J&J) COVID-19 vaccine following six reported US cases of a rare blood clotting event. Although these events are rare, and none have occurred in Connecticut, the Connecticut Department of Public Health recommends that COVID vaccine providers pause on administration of J&J vaccine for the time being while the FDA and CDC complete their review.